Paul W. Hoelscher - Apr 20, 2022 Form 4 Insider Report for Horizon Therapeutics Public Ltd Co (HZNP)

Role
EVP, CFO
Signature
/s/ Miles W. McHugh, Attorney-in-Fact
Stock symbol
HZNP
Transactions as of
Apr 20, 2022
Transactions value $
-$4,628,449
Form type
4
Date filed
4/22/2022, 06:47 PM
Previous filing
Apr 8, 2022
Next filing
Jun 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HZNP Ordinary Shares Options Exercise $1.11M +50K +4766.44% $22.14* 51K Apr 20, 2022 Direct
transaction HZNP Ordinary Shares Sale -$3.25M -28.5K -55.75% $114.36 22.6K Apr 20, 2022 Direct F1, F2
transaction HZNP Ordinary Shares Sale -$2.48M -21.5K -95.36% $115.17 1.05K Apr 20, 2022 Direct F1, F3
holding HZNP Ordinary Shares 66.7K Apr 20, 2022 By LLC F4
holding HZNP Ordinary Shares 72.8K Apr 20, 2022 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HZNP Stock Option (Right to Buy) Options Exercise $0 -50K -57.85% $0.00 36.4K Apr 20, 2022 Ordinary Shares 50K $22.14 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.79 to $114.78 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.82 to $115.48 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The Reporting Person and his spouse share voting power over the securities held by the LLC.
F5 The option is fully vested and exercisable.